The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19
Open accessPublished version of a preprint
Abstract
Significance: Since its emergence in China in December 2019, SARS-CoV-2 has caused a global pandemic. Repurposing of FDA-approved drugs is a promising strategy for identifying rapidly deployable treatments for COVID-19. Herein, we developed a pipeline for quantitative, high-throughput, image-based screening of SARS-CoV-2 infection in human cells that led to the identification of several FDA-approved drugs and clinical candidates with in vitro antiviral activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
UMAP: Uniform Manifold Approximation and Projection
McInnes, L., Healy, J., Saul, N., & Großberger, L. (2018) · Journal of Open Source Software · doi:10.21105/joss.00861 · Cited by 9,826
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Self-citationOu, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108393 · Cited by 1,266
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. (2020) · Science · doi:10.1126/science.abc1560 · Cited by 1,219
Self-citationCOVID-19: combining antiviral and anti-inflammatory treatments
Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30132-8 · Cited by 1,117
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S. Y., Park, S., Shum, D., & Kim, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00819-20 · Cited by 675
Avula, A., Nalleballe, K., Narula, N., Sapozhnikov, S., Dandu, V., Toom, S., Glaser, A., & Elsayegh, D. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.077 · Cited by 558
Quantifying drug combination synergy along potency and efficacy axes
Meyer, C. T., Wooten, D. J., Paudel, B. B., Bauer, J., Hardeman, K. N., Westover, D., Lovly, C. M., Harris, L. A., Tyson, D. R., & Quaranta, V. (2019) · Cell Systems · doi:10.1016/j.cels.2019.01.003 · Cited by 202
Research works printed but not linked: 47
- 10.1053/j.gastro.2020.02.055 · DOI · Paper page
- 10.1136/gutjnl-2020-321013 · DOI · Paper page
- 10.1111/jce.14479 · DOI · Paper page
- 10.1056/NEJMoa1910993 · DOI · Paper page
- 10.1016/j.ddstr.2011.10.002 · DOI · Paper page
- 10.1038/s41586-020-2577-1 · DOI · Paper page
- M. Dittmar . Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep . 35 108959 (2021). · DOI · Paper page
- 10.1016/j.phrs.2020.104960 · DOI
- 10.1371/journal.pbio.2005970 · DOI · Paper page
- 10.1016/j.cell.2020.06.034 · DOI · Paper page
- 10.1073/pnas.2008176117 · DOI · Paper page
- 10.12659/MSM.899591 · DOI
- K. Heiser . Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2. bioRxiv [Preprint] (2020). https://doi.org/10.1101/2020.04.21.054387 (Accessed 3 June 2021). · DOI
- 10.1016/j.stem.2019.12.009 · DOI
- 10.1183/13993003.00607-2020 · DOI · Paper page
- 10.3389/fimmu.2020.01221 · DOI · Paper page
- 10.1371/journal.pone.0023710 · DOI · Paper page
- 10.1016/S0006-291X(86)80253-4 · DOI · Paper page
- 10.1038/aps.2013.200 · DOI · Paper page
- 10.1016/j.cell.2020.04.026 · DOI · Paper page
- 10.1074/jbc.M414139200 · DOI · Paper page
- 10.1159/000450788 · DOI
- 10.3390/cells8080919 · DOI
- 10.1016/j.patter.2020.100090 · DOI
- M. M. Ghahremanpour . Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. ACS Med. Chem. Lett. 11 2526–2533 (2020). · DOI · Paper page
- 10.1016/j.virusres.2017.11.024 · DOI
- 10.1038/sj.leu.2404750 · DOI · Paper page
- 10.1016/j.jmii.2020.03.005 · DOI · Paper page
- 10.1128/JVI.01705-06 · doi:10.1128/jvi.01705-06
- 10.1053/j.gastro.2020.02.054 · DOI · Paper page
- S. Yuan . Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature 593 418–423 (2021). · DOI · Paper page
- 10.1186/1471-2172-6-2 · DOI · Paper page
- 10.14309/ajg.0000000000000664 · DOI · Paper page
- 10.1139/bcb-2020-0035 · DOI
- 10.1007/s10534-014-9742-7 · DOI
- P. Conti ., Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): Anti-inflammatory strategies. J. Biol. Regul. Homeost. Agents 34, 327–331 (2020).
- 10.1002/jmv.25900 · DOI · Paper page
- 10.1016/S0140-6736(20)31042-4 · DOI · Paper page
- 10.1038/s41596-019-0220-0 · DOI · Paper page
- 10.1145/1656274.1656280 · DOI · Paper page
- J.-L. R. Stevens, P. Rudiger, J. A. Bednar, “HoloViews: Building complex visualizations easily for reproducible science” in Proceedings of the 14th Python in Science Conference (SciPy, 2015), pp. 61–69.
- 10.1161/01.CIR.67.6.1347 · DOI · Paper page
- P. C. Feng, C. C. Fenselau, R. R. Jacobson, Metabolism of clofazimine in leprosy patients. Drug Metab. Dispos. 9, 521–524 (1981).
- 10.1002/j.1552-4604.1986.tb02962.x · DOI
- 10.1371/journal.pone.0136369 · doi:10.1371/journal.pone.0136369
- 10.1046/j.0306-5251.2001.01391.x · doi:10.1046/j.0306-5251.2001.01391.x
- C. Mirabelli . Effect of lactoferrin treatment on iAEC2. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE171390. Deposited 2 April 2021.
Cited by
COVID-19: Gastrointestinal Manifestations and Potential Fecal–Oral Transmission
Gu, J., Han, B., & Wang, J. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.054 · Cited by 1,501
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108393 · Cited by 1,266
Barh, D., Tiwari, S., Weener, M. E., Azevedo, V., Góes-Neto, A., Gromiha, M. M., & Ghosh, P. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.104051 · Cited by 90
Frommeyer, T. C., Fursmidt, R. M., Gilbert, M. M., & Bett, E. S. (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.831123 · Cited by 25
Self-citation
Metadata
- Authors
- Mirabelli, C., Wotring, J. W., Zhang, C. J., McCarty, S. M., Fursmidt, R., Pretto, C. D., Qiao, Y., Zhang, Y., Frum, T., Kadambi, N. S., Amin, A. T., O’Meara, T. R., Spence, J. R., Huang, J., Alysandratos, K. D., Kotton, D. N., Handelman, S. K., Wobus, C. E., Weatherwax, K. J., Mashour, G. A., O’Meara, M. J., Chinnaiyan, A. M., & Sexton, J. Z.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2021-08-19
- Volume
- 118
- Issue
- 36
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W3195203505
- Cited by
- 223
- References
- 11
- FWCI
- 13.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- University of Michigan Institute for Clinical and Health Research (NCATS - UL1TR002240, UL1TR002240)
- HHS | NIH | National Cancer Institute (P30CA046592 COVID-19 Administrative Supplement, R35CA231996)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK120623)
- Pharmacological Sciences Training Grant (T32)
- Marie-Slodowska Curie Fellowship (GA - 841247)
- Pulmonary Fibrosis Foundation (Junior Investigator Award)
- HHS | NIH | National Heart, Lung, and Blood Institute (R01HL119215)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (U19AI116482)
- Chan Zuckerberg Initiative (CZF2019-002440)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. https://app.cochat.ai/papers/10.1073/pnas.2105815118
- The paper
- Mirabelli, C., Wotring, J. W., Zhang, C. J., McCarty, S. M., Fursmidt, R., Pretto, C. D., Qiao, Y., Zhang, Y., Frum, T., Kadambi, N. S., Amin, A. T., O’Meara, T. R., Spence, J. R., Huang, J., Alysandratos, K. D., Kotton, D. N., Handelman, S. K., Wobus, C. E., Weatherwax, K. J., . . . Sexton, J. Z. (2021). Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2105815118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.